Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.
Actively Recruiting
Researchers are evaluating the efficacy and safety of orforglipron in adults with overweight who are at risk of developing obesity-related complications such as type 2 diabetes, hypertension, and dyslipidemia, or progressing to class 1 obesity. The study is a phase 3, randomized, double-blind, placebo-controlled trial that aims to understand whether this oral medication can reduce these risks over a two-year period. Participants will be randomly assigned to one of three groups receiving orforglipron orally throughout, orforglipron followed by placebo, or placebo followed by orforglipron. The study involves daily oral administration of these medications. The trial includes a long-term treatment period lasting up to 104 weeks about two years, during which participants are monitored for weight changes and the onset of obesity-related health issues. Throughout the study, participants will undergo regular assessments including measurements of body weight, waist circumference, blood pressure, blood markers like glycated hemoglobin and triglycerides, and quality of life questionnaires. Researchers will also monitor the time to onset of obesity-related complications and pharmacokinetics of orforglipron at specified intervals. Safety and effectiveness will be tracked continuously, with the primary outcome being the time until the development of obesity-related complications or progression to class 1 obesity.
Actively Recruiting
This trial evaluates the efficacy, safety, and tolerability of switching from glucagon-like peptide-1 receptor agonists GLP-1RA to maridebart cafraglutide in adults with obesity or overweight. It aims to assess how maridebart cafraglutide affects body weight and other safety measures in this population. The study is a Phase 3, open-label, randomized trial sponsored by Amgen. Participants are randomly assigned to one of two dosing schedules of maridebart cafraglutide, which is administered via subcutaneous injection. The treatment period involves receiving one of these dosing regimens to compare their effects. The study focuses on switching from prior weekly GLP-1RA treatment to maridebart cafraglutide and monitors participants throughout the treatment. During the trial, participants will have their body weight measured at baseline and at Week 68 to determine the percentage change. Additional assessments include plasma concentration of maridebart cafraglutide and monitoring for treatment-emergent adverse events up to 84 weeks. Participants are expected to maintain stable body weight and gastrointestinal tolerability before and during the trial, with contraception required for females. Overall, the study duration extends through the treatment period and safety follow-up.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ABBV-295, a long-acting amylin analog, for adults with obesity or overweight who also have weight-related health conditions. The study aims to compare different doses of ABBV-295 with a placebo to see how well they reduce body weight by Week 32. This phase 2 trial involves about 360 adult participants across multiple sites in the United States and Puerto Rico. Participants will be randomly assigned to receive one of several doses of ABBV-295 or a placebo. The treatment is given as subcutaneous injections using pre-filled syringes. Dose escalation will occur during the 52-week Double-Blind Period until reaching a maintenance dose. Participants will not know which treatment they receive, and all groups follow a similar dosing schedule. Throughout the study, participants will attend regular visits at clinics or hospitals for medical assessments, blood tests, and questionnaires to monitor weight changes and any side effects. The primary outcomes include the percentage change in body weight from baseline to Week 32 and the number of participants experiencing adverse events up to Week 52. The study lasts for 52 weeks of treatment with ongoing safety monitoring.